Investigating the role of specific proteins in lung injury and recovery
Official title: MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
Funded at University of Washington · NIH-10912808 · Data updated 2026-11-12
This study is looking at how specific proteins affect lung inflammation and injury in people with Acute Respiratory Distress Syndrome (ARDS), with the hope of finding new treatments that can help patients recover better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 24, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $717,227 |
| NIH project number | 5R01HL167273-02 |
| Project ID | NIH-10912808 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing or at risk for Acute Respiratory Distress Syndrome, particularly those with severe lung inflammation.
✕Less likely to help
Patients with chronic lung conditions or those not experiencing acute lung injury may not benefit from this research.
What this research studies
This research focuses on understanding how certain proteins, specifically MAP2K1 and MAP2K2, influence lung inflammation and injury, particularly in cases of Acute Respiratory Distress Syndrome (ARDS). By studying both human and rodent models, the researchers aim to identify pathways that could lead to new treatments for lung injury. The approach involves manipulating macrophage behavior to enhance recovery from lung damage, with promising results observed in preclinical models. The ultimate goal is to develop targeted therapies that improve patient outcomes in ARDS.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve recovery from acute lung injuries like ARDS.
How similar studies have gone: Previous research has shown that targeting similar pathways in lung injury models can lead to improved outcomes, indicating a promising avenue for this approach.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Manicone, Anne M. — University of Washington
- Study coordinator: Manicone, Anne M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.